The trial is evaluating the potential of NT-I7 to enhance the expansion, persistence, and stemness of CAR-T cells in LBCL patients. Credit: Lightspring/Shutterstock.

NeoImmuneTech has announced interim findings from its Phase Ib clinical trial of the combination of a CAR-T therapy with NT-I7 (efineptakin alfa) in treating large B-cell lymphoma (LBCL).

The trial, known as NIT-112, is evaluating the safety, tolerability, and recommended Phase II dose (RP2D), as well as NT-I7’s potential to enhance the expansion, persistence, and stemness of CAR-T cells in LBCL patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This trial enrolled patients who had received established CAR-T therapies such as Kymriah, Yescarta, or Breyanzi, followed by an NT-I7 dose 21 days post-infusion.

The interim results highlighted that mid-level doses of NT-I7 (360, 480 µg/kg) maintained a stable safety profile.

No cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed, which are typically high-risk side effects associated with CAR-T treatments.

The trial observed only mild side effects, such as injection site erythema and swelling, in six out of 11 participants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These side effects were said to be manageable and did not escalate beyond Grade 1-2 severity.

Furthermore, the addition of NT-I7 led to a significant increase in the amplification of CAR-T cells, extended their presence in the body, and enhanced T cell stemness.

The interim analysis also revealed an impressive overall response rate (ORR) of 81.1% among the patients, with seven achieving a complete response (CR) and two a partial response (PR).

This ORR is claimed to be notably higher than the 52% reported for Kymriah alone in LBCL patients.

NeoImmuneTech president and CEO Dr Luke Oh said: “We are thrilled by the preliminary results of study NIT-112 showing NT-I7’s ability to amplify CAR-T cells. This successful amplification of CAR-T cells is expected to translate into improved patient outcomes.

“NIT plans to actively pursue technology transfer related to the combination of NT-I7 with CAR-T therapies and we look forward to accelerating our discussions with the organisations already conducting preclinical studies combining NT-I7 with our own CAR-T technologies.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.